Scientific Advisory Board
Professor Guido Cavaletti
MD, Board in Neurology. Senior consultant neurologist and head of the Neuroimmunology Center, S. Gerardo Hospital, Monza (Italy). Head of the Experimental Neurology Unit at the School of Medicine and Surgery and Director of the PhD program in Neuroscience, University of Milano-Bicocca, Monza. Deputy Scientific Director of the Milan Center for Neuroscience (NeuroMI). Past-president of the Associazione Italiana per lo Studio delle Neuropatie Periferiche (equivalent to Italian Peripheral Nerve Society) and former member of the Board of Directors of the Peripheral Nerve Society. Coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity. He authored more than 250 peer-reviewed papers (H-index = 44)
Professor David Cella
Professor David Cella is the Ralph Seal Paffenbarger Professor and Chair of the Department of Medical Social Sciences at the Northwestern University Feinberg School of Medicine. He studies questions regarding quality of life measurement in clinical trials, cross-cultural equivalence of quality of life measurement, efficacy of psychosocial interventions in chronic illness, and medical outcomes research. He has published more than 700 peer-reviewed articles, most of which focus on the unique contribution that the patient perspective has upon the evaluation of health and health care. Dr. Cella has studied quality of life as a scientific enterprise, bringing the voice of the patient into consideration of value and opportunities for improvement. Dr. Cella developed and is continually refining the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System for outcome evaluation in patients with chronic medical conditions. He was steering committee chair and principal investigator of the statistical coordinating center for the NIH Roadmap Initiative to build a Patient Reported Outcome Measurement Information System (PROMIS) and is currently the principal investigator of the PRO Core of the Environmental Influences on Child Health Outcomes (ECHO) NIH initiative. Dr. Cella is a past recipient of President’s Award, International Society for Quality of Life Research (2008), the Health Assessment Laboratory/Medical Outcomes Trust John Ware and Alvin Tarlov Career Achievement Award in Patient Reported Outcomes Measures (2014), the National Academy of Medicine (Institute of Medicine) Gustav O. Lienhard Award (2016).
Professor Emeritus in oncology at the University of Uppsala and Consultant at the University hospital. Between 1998 and 2014 he was also professor at Karolinska Institutet, Stockholm and consultant at the Karolinska University Hospital. He has been responsible for the care of patients with gastrointestinal cancer at the hospitals until his retirement in 2014.
Professor Glimelius main research areas deal with tumour biology, gastrointestinal cancer, malignant lymphomas, radiotherapy and psychosocial care. In gastrointestinal cancer and malignant lymphomas he has been the principal or co-investigator of numerous trials. He has published more than 600 research articles and chapters in different textbooks within the research areas, made important contributions to the benefit of many patients and directed about 50 doctoral students to their PhD theses.
Professor Glimelius has lectured at many international conferences, chaired several consensus conferences, official investigations, been a member of many scientific councils evaluating research proposals and projects.
He is the Chief Editor of Acta Oncologica and member of the Editorial Board of several scientific journals. He was the vice chairman for 6 years of the Research Council, Swedish Cancer Society. He has also received several awards and honours.
Rolf Karlsten MD
Associate professor, board certified specialist in anesthesiology/intensive care and pain management and has a diploma in pharmaceutical medicine. He is currently Head of Rehabilitation Medicine and the Multidisciplinary Pain Centre at Uppsala University hospital, Sweden. He has a PhD in pain research focusing neuropathic pain mechanisms. His research is now focusing on pain mechanisms, neuropathy, neuropathic pain and pain rehabilitation. He has 15 years’ experience of pharmaceutical development, 10 years at AstraZeneca as Medical Science Director (clinical development, neuroscience) and since 2013 as consultant for a variety of companies.
…and we have a fifth undisclosed member who is a US expert and KOL in CIPN